CTXR News and Press, Citius Pharmaceuticals Inc. From 12/23/25

2025-12-23 16:35:04 ET More on Citius Pharmaceuticals Citius Pharmaceuticals GAAP EPS of -$3.38 misses by $0.25 Citius Oncology announces $18 million registered direct offering Seeking Alpha’s Quant Rating on Citius Pharmaceuticals Historical earnings ...

2025-12-23 16:32:47 ET More on Citius Pharmaceuticals Citius Oncology announces $18 million registered direct offering Seeking Alpha’s Quant Rating on Citius Pharmaceuticals Historical earnings data for Citius Pharmaceuticals Financial information for ...

Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update PR Newswire Subsidiary, Citius Oncology, launches cancer immunotherapy, LYMPHIR™, in the U.S. in December 2025 CRANFORD, N.J. , Dec. 23, 2025 /PRNewswire/ -- Citi...

Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update PR Newswire Cancer Immunotherapy, LYMPHIR™, launched in the U.S. in December 2025 Completed $36 million in strategic financings, of which $18 million was via private place...

2025-12-09 08:49:45 ET More on Citius Pharmaceuticals, Citius Oncology Seeking Alpha’s Quant Rating on Citius Pharmaceuticals Historical earnings data for Citius Pharmaceuticals Financial information for Citius Pharmaceuticals Seeking Alpha’s Qu...

Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules PR Newswire Proceeds strengthen cash position and support commercial launch of LYMPHIR™, a novel cancer immunotherapy for cutaneous T-cel...

Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim PR Newswire Partnership expands access to LYMPHIR for patients with cutaneous T-cell lymphoma across Turkey , Bahrain , Qatar , Oman , Kuwait , Sau...

Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) PR Newswire LYMPHIR now available nationwide CRANFORD, N.J. , Dec. 1, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nas...

Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration PR Newswire Leading edge artificial intelligence and machine learning platform supports enhanced salesforce targeting and engagement for cutaneous T-cell lymphoma immunotherapy launch CRA...

Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules PR Newswire CRANFORD, N.J. , Oct. 21, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a bioph...